Promising oncolytic agents for metastatic breast cancer treatment.
作者： Douglas Hurst , James Cody
DOI: 10.2147/OV.S63045
关键词:
摘要: New therapies for metastatic breast cancer patients are urgently needed. The long-term survival rates remain unacceptably low with recurrent disease or disseminated metastases. In addition, existing often cause a variety of debilitating side effects that severely impact quality life. Oncolytic viruses constitute developing therapeutic modality in which interest continues to build due their ability spare normal tissue while selectively destroying tumor cells. A number different have been used develop oncolytic agents cancer, including herpes simplex virus, adenovirus, vaccinia measles reovirus, and others. general, clinical trials several cancers demonstrated excellent safety records evidence efficacy. However, the impressive responses observed preclinical studies yet be realized clinic. order promise virotherapy fully patients, effectiveness must disease. This review provides summary strategies being developed target cancer.
sci-hub.se 参考文章(132)
L W Wood, E J Shillitoe, Effect of a caspase inhibitor, zVADfmk, on the inhibition of breast cancer cells by herpes simplex virus type 1 Cancer Gene Therapy. ,vol. 18, pp. 685- 694 ,(2011) , 10.1038/CGT.2011.34
S Leveille, S Samuel, M-L Goulet, J Hiscott, Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Therapy. ,vol. 18, pp. 435- 443 ,(2011) , 10.1038/CGT.2011.14
Jeff L. Hummel, Ekaterina Safroneeva, Karen L. Mossman, The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma Molecular Therapy. ,vol. 12, pp. 1101- 1110 ,(2005) , 10.1016/J.YMTHE.2005.07.533
Patrizia Nanni, Valentina Gatta, Laura Menotti, Carla De Giovanni, Marianna Ianzano, Arianna Palladini, Valentina Grosso, Massimiliano Dall'Ora, Stefania Croci, Giordano Nicoletti, Lorena Landuzzi, Manuela Iezzi, Gabriella Campadelli-Fiume, Pier-Luigi Lollini, Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus PLoS Pathogens. ,vol. 9, pp. e1003155- ,(2013) , 10.1371/JOURNAL.PPAT.1003155
Prem Seth, Zhen-Guo Wang, Amanda Pister, M. Behzad Zafar, Sung Kim, Theresa Guise, Lalage Wakefield, Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-β receptor II and human immunoglobulin Fc for breast cancer therapy Human Gene Therapy. ,vol. 17, pp. 1152- 1160 ,(2006) , 10.1089/HUM.2006.17.1152
Anna Israyelyan, Edward John Shannon, Abolghasem Baghian, Michael T. Kearney, Konstantin G. Kousoulas, Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn. Cancer Chemotherapy and Pharmacology. ,vol. 64, pp. 1201- 1210 ,(2009) , 10.1007/S00280-009-0987-8
Jean-Simon Diallo, Fabrice Le Boeuf, Frances Lai, Julie Cox, Markus Vaha-Koskela, Hesham Abdelbary, Heather MacTavish, Katherine Waite, Theresa Falls, Jenny Wang, Ryan Brown, Jan E Blanchard, Eric D Brown, David H Kirn, John Hiscott, Harry Atkins, Brian D Lichty, John C Bell, None, A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers Molecular Therapy. ,vol. 18, pp. 1123- 1129 ,(2010) , 10.1038/MT.2010.67
M Opyrchal, C Allen, P Msaouel, I Iankov, E Galanis, Inhibition of Rho-associated coiled-coil-forming kinase increases efficacy of measles virotherapy. Cancer Gene Therapy. ,vol. 20, pp. 630- 637 ,(2013) , 10.1038/CGT.2013.58
Erika Vacchelli, Alexander Eggermont, Catherine Sautès-Fridman, Jérôme Galon, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi, Trial Watch-Oncolytic viruses and cancer therapy. OncoImmunology. ,vol. 2, ,(2016) , 10.4161/ONCI.24612
John Nemunaitis, Alex W Tong, Michael Nemunaitis, Neil Senzer, Anagha P Phadke, Cynthia Bedell, Ned Adams, Yu-An Zhang, Phillip B Maples, Salina Chen, Beena Pappen, James Burke, Daiju Ichimaru, Yasuo Urata, Toshiyoshi Fujiwara, A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors Molecular Therapy. ,vol. 18, pp. 429- 434 ,(2010) , 10.1038/MT.2009.262